within Pharmacolibrary.Drugs.ATC.C;

model C09DA07
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.0008333333333333334,
    adminDuration  = 600,
    adminMass      = 80 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.5,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 12.0,            
    Vdp             = 0.2,
    k12             = 150,
    k21             = 150
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C09DA07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Combination product containing telmisartan, an angiotensin II receptor antagonist, and hydrochlorothiazide, a thiazide diuretic, used for the management of hypertension in adults. Approved and in use today for lowering blood pressure and reducing cardiovascular risk.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for a typical adult patient (no sex difference assumed) receiving oral telmisartan 80 mg and hydrochlorothiazide 25 mg, based on single-dose studies of each component and population PK literature for the combination, as no explicit published PK model for the combination exists.</p><h4>References</h4><ol><li><p>Moon, SJ, et al., &amp; Kim, MG (2019). Pharmacokinetic Interaction Among Telmisartan, Amlodipine, and Hydrochlorothiazide After a Single Oral Administration in Healthy Male Subjects. <i>Clinical therapeutics</i> 41(11) 2273–2282. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2019.08.020&quot;>10.1016/j.clinthera.2019.08.020</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31564513/&quot;>https://pubmed.ncbi.nlm.nih.gov/31564513</a></p></li><li><p>Young, CL, et al., &amp; Stangier, J (2000). Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. <i>Journal of clinical pharmacology</i> 40(12 Pt 1) 1323–1330. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11185630/&quot;>https://pubmed.ncbi.nlm.nih.gov/11185630</a></p></li><li><p>Fenton, C, et al., &amp; Scott, LJ (2003). Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension. <i>Drugs</i> 63(19) 2013–2028. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200363190-00006&quot;>10.2165/00003495-200363190-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12962518/&quot;>https://pubmed.ncbi.nlm.nih.gov/12962518</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C09DA07;
